Daratumumab injection (DrugBank: Daratumumab)
4 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
16 | クロウ・深瀬症候群 | 1 |
28 | 全身性アミロイドーシス | 0 |
63 | 特発性血小板減少性紫斑病 | 0 |
222 | 一次性ネフローゼ症候群 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04396496 (ClinicalTrials.gov) | September 22, 2020 | 15/5/2020 | Treatment of POEMS Syndrome With Daratumumab | A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab | POEMS Syndrome | Drug: Daratumumab Injection | University of Arkansas | Janssen Scientific Affairs, LLC | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |